Regulus Therapeutics (RGLS) Price Target Raised to $34 at BMO; Could Attract Interest from Big Pharma, Says Analyst
Tweet Send to a Friend
BMO Capital maintained an Outperform rating on Regulus Therapeutics (NASDAQ: RGLS) and raised its price target to $34.00 (from $18.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
